SCHEMBL657027

SCHEMBL657027

Oc1ccc(N2CCCC2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.57
MAPT P10636 7/20 0.57
KDM4E B2RXH2 6/20 0.57
PKM P14618 1/20 0.57
CTSL P07711 1/20 0.56
CTSB P07858 1/20 0.56
GAA P10253 4/20 0.54
ALOX15 P16050 3/20 0.54
L3MBTL1 Q9Y468 3/20 0.54
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
NPC1 O15118 3/20 0.54
TP53 P04637 3/20 0.54
RAB9A P51151 3/20 0.54
HSD17B10 Q99714 2/20 0.54
NPSR1 Q6W5P4 2/20 0.54
USP2 O75604 1/20 0.54
POLB P06746 1/20 0.54
THRB P10828 1/20 0.54
HTT P42858 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20748279 0.97 ALDH1A1 (0.58) ALDH1A1MAPTKDM4EPKMCTSL
SCHEMBL2947895 0.97 ALDH1A1 (0.58) ALDH1A1MAPTKDM4EPKMCTSL
Hydrochloric Acid SCHEMBL11794645 0.97 ALDH1A1 (0.58) ALDH1A1MAPTKDM4EPKMCTSL
Hydrochloric Acid SCHEMBL29157420 0.95 ALDH1A1 (0.61) ALDH1A1MAPTKDM4EPKMCTSL
SCHEMBL3043144 0.95 ALDH1A1 (0.57) ALDH1A1MAPTKDM4EPKMCTSL
SCHEMBL7106841 0.92 KDM4E (0.61) ALDH1A1MAPTKDM4EPKMCTSL
SCHEMBL11726853 0.91 ALDH1A1 (0.52) ALDH1A1MAPTKDM4EPKMCTSL
SCHEMBL7041242 0.89 MAPT (0.68) ALDH1A1MAPTKDM4EPKMGAA
SCHEMBL19935557 0.87 MEN1 (0.48) ALDH1A1MAPTKDM4EPKMCTSL
SCHEMBL20580177 0.87 MEN1 (0.48) ALDH1A1MAPTKDM4EPKMCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111018901-B Zanamivir and ranamivir intermediate and synthesis method thereof 中国科学院上海有机化学研究所 2021-09-03 CN claimed
CN-111116567-A Zanamivir and ranamivir intermediate and synthesis method thereof 中国科学院上海有机化学研究所 2020-05-08 CN claimed
CN-111018901-A Zanamivir and ranamivir intermediate and synthesis method thereof 中国科学院上海有机化学研究所 2020-04-17 CN claimed
CN-104418876-B Zanamivir and ranamivir intermediate and synthesis method thereof 中国科学院上海有机化学研究所 2019-05-17 CN claimed
CN-102993211-B Azacyclo-substituted benzo spirooxazine photochromic compound and preparation method thereof TIANJIN FORESEEN TECHNOLOGY CO LTD 2015-04-01 CN claimed
EP-1458393-B1 SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS GLAXO GROUP LTD (GB) 2008-06-25 EP claimed
US-20250134907-A1 FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2025-05-01 US disclosed
EP-4476222-A1 FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF The United States of America, as represented by the Secretary, Department of Health and Human Services (US) 2024-12-18 EP disclosed
EP-3691642-B1 [1,6]NAPHTHYRIDINE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2024-03-06 EP disclosed
CN-111116567-B Zanamivir and ranamivir intermediates and synthesis method thereof 中国科学院上海有机化学研究所 2023-10-10 CN disclosed
WO-2023154197-A1 FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2023-08-17 WO disclosed
CN-111163775-B Novel [1,6] naphthyridine compounds and derivatives as CDK8/CDK19 inhibitors 勃林格殷格翰国际有限公司 2023-07-11 CN disclosed
CN-115417751-A Method for hydroxylation of benzene ring C-H phenol 中山大学 2022-12-02 CN disclosed
EP-0005379-B1 PHOTOSENSITIVE COMPOSITIONS CONTAINING CARBONYLIC HALIDES AS ACTIVATORS Dynachem Corporation (US) 1981-12-23 EP disclosed
US-4223036-A FUNGICIDES, BACTERICIDES JANSSEN PHARMACEUTICA N.V. (BE) 1980-09-16 US disclosed
EP-0005379-A2 Photosensitive compositions containing carbonylic halides as activators Dynachem Corporation (US) 1979-11-14 EP disclosed
EP-0005380-A2 Phototropic photosensitive compositions containing a fluoran colorformer Dynachem Corporation (US) 1979-11-14 EP disclosed
US-4144346-A FUNGICIDES, BACTERICIDES JANSSEN PHARMACEUTICA N.V. (BE) 1979-03-13 US disclosed
US-4084969-A SILVER IODIDE, DEVELOPMENT IN PRESENCE OF TRIVALENT COBALT COMPLEX FUJI PHOTO FILM CO., LTD. (JA) 1978-04-18 US disclosed
US-3959571-A PRESSURE OR HEAT SENSITIVE COPYING PAPER SHIN NISSO KAKO CO., LTD. (JA) 1976-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250134907-A1 FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF RXFP3, RXFP4, RXFP2 ALDH1A1 4818/4885MAPT 4869/4885KDM4E 4024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.